Loading…
Reckitt Q3 2025: Strong 7% LFL growth driven by volumes. Guidance maintained, strategic momentum builds.
This article covers information on Reckitt Benckiser Group PLC.
LON:RKTLast updated:
Reckitt posted a strong third quarter, with Group like-for-like (LFL) net revenue up 7.0% to £3,611m. The quality of growth improved too: volumes did more of the lifting. Group volumes rose 4.2% with price/mix up 2.8%.
The engine room was Core Reckitt – the consumer health and hygiene portfolio – where LFL growth hit 6.7% on a neat balance of volume (+3.4%) and price/mix (+3.3%). Management reiterated full-year guidance and sounded confident about delivery.
| Metric (Q3 2025 unless stated) | Reported |
|---|---|
| Group net revenue (IFRS) | £3,611m |
| Group LFL growth | +7.0% (volume +4.2%, price/mix +2.8%) |
| Core Reckitt LFL growth | +6.7% to £2,603m |
| Emerging Markets LFL | +15.5% to £1,080m |
| Europe LFL | +0.8% to £865m |
| North America LFL | +1.3% to £658m |
| Mead Johnson Nutrition LFL | +22.0% to £529m |
| Essential Home LFL | -4.9% to £479m |
| YTD Group LFL | +3.3% on £10,591m revenue (IFRS -0.3% after FX) |
| Share buyback | £1.0bn programme; first £250m tranche completed |
| FY 2025 Group LFL guidance | +3% to +4% (maintained) |
| Other guidance | Adj. net finance expense £350m-£370m; tax ~25%; capex 3%-4% of revenue |
Emerging Markets were the standout, up 15.5% LFL to £1,080m with a healthy split of volume (+7.4%) and price/mix (+8.1%). China delivered broad-based double-digit growth across Dettol, Durex, Veet, Intima and VMS lines, aided by new product variants and upgraded formulas.
India’s sell-in was muted in Q3 due to a GST regime change that shifted orders into Q4, but YTD LFL remains high single digit. Latin America was mixed: softer Brazil offset by growth in Mexico. Management also called out double-digit growth in smaller, high-potential markets like Indonesia, Malaysia and Colombia.
Europe eked out 0.8% LFL growth to £865m despite a tough pricing backdrop, with volume down 0.5% but improving sequentially from Q1 (-4.7%) and Q2 (-1.9%). Premiumisation helped, notably in Finish Ultimate Plus, while Self Care brands Gaviscon and Nurofen performed well.
Category growth across the area was broadly flat, and Western Europe remains a tricky pricing environment. Still, four of six regions grew LFL in the quarter – progress.
North America returned to LFL growth at 1.3% to £658m, volume +2.3% and price/mix -1.0%. Excluding seasonal over-the-counter (OTC) cold and flu, the region posted mid single-digit growth, led by Lysol momentum (including Air Sanitiser and Laundry Sanitiser), resilient Finish and a good showing from Neuriva.
Seasonal OTC was the drag, declining mid single digit as the category lapped a Covid-driven spike in Q3 2024. The transition to a PE-free Mucinex Sinus formulation “landed as anticipated”, setting up for the winter season.
Self Care grew 5.6% LFL to £859m (volume +1.2%, price/mix +4.4%). Strip out seasonal OTC and growth was a punchier 12.3% LFL, powered by VMS in China plus Gaviscon and favourable Nurofen phasing in Europe. Seasonal OTC declined 3.4% LFL in the quarter and is down 7.8% YTD.
Germ Protection rose 9.2% LFL to £838m, with most of that from volume (+8.2%). Dettol had another double-digit quarter led by China and MENARP, and Lysol posted high single-digit volume-led growth in North America.
Intimate Wellness jumped 13.5% LFL to £375m, with price/mix a hefty +10.9% and volume +2.6%. Durex grew strongly in China, ASEAN and MENARP, aided by innovations like Durex Intensity and Benzocaine upgrades. Intima continues to resonate in China, with LFL revenue more than doubling YTD.
Household Care was flat to modestly positive at +0.2% LFL to £531m. Finish grew in Emerging Markets and held up in North America, while Europe remained challenging. Vanish was mixed – up mid single digit in Emerging Markets and down mid single digit in Europe.
Mead Johnson delivered 22.0% LFL growth to £529m, split between volume (+12.4%) and price/mix (+9.6%). This partly reflects an easy comparator after the July 2024 tornado destroyed its primary U.S. warehouse. YTD LFL is +4.0%, with international business growing low single digit in Q3 alongside North America’s recovery.
Essential Home declined 4.9% LFL to £479m. Volumes were slightly positive (+0.6%) but price/mix was negative (-5.5%). Europe performed “as expected”, but Brazil’s pest category remained weak and U.S. Air Care softened. YTD LFL is -6.0% as the business heads for divestment, which Reckitt expects to complete by 31 December 2025.
Full-year guidance is unchanged: Group LFL growth of 3% to 4%; Core Reckitt above 4%; Mead Johnson Nutrition low-to-mid single-digit growth; Essential Home a mid single-digit decline (trimmed from low single-digit decline previously).
The Fuel for Growth programme is expected to drive adjusted operating profit ahead of net revenue growth, and management expects another year of adjusted diluted EPS growth. On capital allocation, the £1 billion share buyback started on 28 July 2025; the first £250m tranche has been completed. Technical guidance: adjusted net finance expense £350m to £370m, adjusted effective tax rate around 25%, and capex at 3% to 4% of net revenue.
Overall, this was a clean quarter: volumes up, innovations landing, Emerging Markets firing, and guidance intact. There are moving parts – seasonal OTC, FX and Essential Home – but the trajectory in Core Reckitt looks encouraging. For long-term holders, this reads as steady execution with strategic housekeeping well underway.
Related
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Impax Q3 AUM rises to £23.3bn despite £1.7bn net outflows, driven by market gains and strong investment performance.
JoshuaJuly 10, 2026
MJ Gleeson FY2026 trading update: steady profits, mixed home sales with operational restructuring improving outlook.
JoshuaJuly 10, 2026
Last updated
Category
InvestingViews
142 viewsLikes
No ratings yet
No comments yet - start the conversation.